Literature DB >> 25794940

The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis.

Stacey A Sakowski1, Eva L Feldman.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25794940      PMCID： PMC4404463          DOI： 10.1007/s13311-015-0349-7

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  12 in total

Review 1.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 3.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 4.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis.

Authors:  Esther Verstraete; Bradley R Foerster
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 7.  Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Stephen A Goutman; Kevin S Chen; Eva L Feldman
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 8.  Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Authors:  Neta Zach; David L Ennist; Albert A Taylor; Hagit Alon; Alexander Sherman; Robert Kueffner; Jason Walker; Ervin Sinani; Igor Katsovskiy; Merit Cudkowicz; Melanie L Leitner
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 9.  Spinal Muscular Atrophy Therapeutics: Where do we Stand?

Authors:  Constantin d'Ydewalle; Charlotte J Sumner
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 10.  The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.

Authors:  Johnathan Cooper-Knock; Janine Kirby; Robin Highley; Pamela J Shaw
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620
View more
  1 in total

Review 1.  The Interplay Between Neuroinfections, the Immune System and Neurological Disorders: A Focus on Africa.

Authors:  Leonard Ngarka; Joseph Nelson Siewe Fodjo; Esraa Aly; Willias Masocha; Alfred K Njamnshi
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.